In a patient with atrial fibrillation currently taking apixaban 5 mg twice daily, flecainide 50 mg twice daily, and metoprolol tartrate 50 mg twice daily, should these medications be continued until the planned catheter ablation?

Continue All Three Medications Until Ablation

Yes, continue apixaban 5 mg twice daily, flecainide 50 mg twice daily, and metoprolol tartrate 50 mg twice daily until the planned catheter ablation. This regimen aligns with current ESC guidelines and ensures optimal stroke prevention, rhythm control, and rate control during the pre-ablation period.

Anticoagulation Management

Uninterrupted apixaban is mandatory and must be continued through the ablation procedure. The 2024 ESC guidelines explicitly recommend uninterrupted oral anticoagulation in patients undergoing AF catheter ablation to prevent peri-procedural ischemic stroke and thromboembolism 1.

• Do not stop apixaban before the procedure - the ablation center will manage peri-procedural anticoagulation 1
• Apixaban must have been initiated at least 3 weeks prior to ablation, which this patient has already satisfied 1
• The FDA label warns that premature discontinuation of apixaban increases thrombotic risk and recommends considering coverage with another anticoagulant if discontinued 2
• After ablation, continue anticoagulation for at least 2 months regardless of rhythm outcome, then base long-term decisions on CHA2DS2-VA score, not perceived ablation success 1

Rhythm Control Strategy

Continue flecainide 50 mg twice daily as appropriate pre-ablation rhythm control therapy. The 2024 ESC guidelines recommend flecainide for long-term rhythm control to prevent AF recurrence and progression, specifically excluding patients with impaired left ventricular systolic function, severe left ventricular hypertrophy, or coronary artery disease 1.

• Flecainide is appropriate assuming this patient has no structural heart disease, heart failure, or significant coronary disease 1
• The combination of flecainide with metoprolol has demonstrated superior efficacy in reducing AF recurrences compared to flecainide alone, particularly in persistent AF (71.1% vs 43.6% freedom from recurrence, P=0.025) 3
• This combination also improves quality of life and tolerability with fewer side effects 3

Rate Control Strategy

Continue metoprolol tartrate 50 mg twice daily for rate control and synergistic rhythm control benefits. Beta-blockers remain first-line agents for rate control in AF 4.

• The beta-blocker provides rate control during any AF episodes that occur before ablation 4
• Metoprolol enhances flecainide's anti-arrhythmic efficacy and reduces side effects when used in combination 3
• Important caveat: Metoprolol does not significantly interact with apixaban metabolism, unlike diltiazem which increases bleeding risk by 5.4 events per 1000 person-years when combined with factor Xa inhibitors 5

Pre-Ablation Considerations

The current medication regimen optimally prepares this patient for catheter ablation:

• Rhythm control with flecainide may reduce AF burden before the procedure 1
• Adequate anticoagulation prevents thrombus formation that could complicate the ablation 1
• Rate control ensures hemodynamic stability if AF recurs 4

Critical Safety Points

Verify the patient has no contraindications to flecainide before continuing:

• No history of myocardial infarction or coronary artery disease 1
• No heart failure with reduced ejection fraction 1
• No severe left ventricular hypertrophy 1
• No advanced conduction disturbances unless paced 1

Confirm appropriate apixaban dosing - the 5 mg twice daily dose is correct unless the patient has at least 2 of the following: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 2, 6. Inappropriate dose reduction (which occurs in 60.8% of cases in clinical practice) should be avoided 7.

Do not substitute diltiazem for metoprolol as this significantly increases bleeding risk when combined with apixaban or rivaroxaban (rate difference 5.4 per 1000 person-years, with higher risk at doses >120 mg/day) 5.